The drug panel consisted of one hundred drugs, including novel chemotherapeutics that are undergoing clinical development. Striking and specific responses were found for venetoclax (ABT-199), a drug that specifically targets the BCL2 protein, and which has been shown to work in other cancer strains. Follow-up work in mouse models have shown that the drug induces remission when combined with backbone chemotherapy for ALL.
Read More